Septerna, Inc. (SEPN)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. (“Septerna” or “the Company”) (NASDAQ: SEPN). Investors who purchased Septerna securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether Septerna has violated federal securities laws.

Investigation Details

On or around October 25, 2024, Septerna conducted its initial public offering (“IPO”) of 18.4 million shares of common stock priced at $18.00 per share. Then, on February 18, 2025, Septerna issued a press release “announc[ing] its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786 in healthy volunteers.” Septerna said that its “decision follows the observation of two unanticipated severe (Grade 3) events of elevated unconjugated bilirubin in the MAD portion of the Phase 1 trial, both of which were without elevations in ALT, AST, and GGT liver enzyme levels.” On this news, Septerna’s stock price fell $6.09 per share, or 46.99%, to close at $6.87 per share on February 18, 2025.

What’s Next?

If you are aware of any facts relating to this investigation or purchased Septerna securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]